Skip to content
Biodatica
Start free

OncoHost Ltd.

Birmingham, Alabama

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: Adjuvant Quisinostat in High-Risk Uveal Melanoma

4w agoTrial registeredJun 18, 2026Source filing (opens the source filing in a new tab)

Momentum

90no change

Momentum 90 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,843 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    May 27, 2025

    Uveal Melanoma · RECRUITING · sponsor: University of Miami · Adjuvant Quisinostat in High-Risk Uveal Melanoma

    ClinicalTrials.gov · NCT06932757 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Nov 13, 2024

    HLA-A2 Positive Cells Present, Refractory Melanoma · TERMINATED · sponsor: Roswell Park Cancer Institute · Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

    ClinicalTrials.gov · NCT04093323 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Jul 16, 2024

    Stage II-III Non-small Cell Lung Cancer · RECRUITING · sponsor: Sheba Medical Center · Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection

    ClinicalTrials.gov · NCT07131163 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Sep 5, 2023

    Malignant Melanoma, Metastatic Melanoma, Immunotherapy, BRAF V600E, Malignant Melanoma Stage IV · COMPLETED · sponsor: Dr. Ronnie Shapira · Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma

    ClinicalTrials.gov · NCT05304546 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Nov 10, 2020

    Metastatic Uveal Melanoma · COMPLETED · sponsor: Jose Lutzky, MD · Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

    ClinicalTrials.gov · NCT04552223 (opens the source filing in a new tab)

  6. Trial

    Study registered

    Oct 1, 2019

    Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma · ACTIVE_NOT_RECRUITING · sponsor: OncoHost Ltd. · Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

    ClinicalTrials.gov · NCT04056247 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources